statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the...

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside...

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished...

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting...

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM Research Report) on March 25 and set a price target of $36...

Verastem's Strategic Advancements and Financial Stability Underscore Buy Rating

This price move could indicate a change in the trend, and may be a sell signal for investors...

Verastem (VSTM, $11.53) price exceeded its 50-day Moving Average on March 25, 2024

This is a Bullish indicator signaling VSTM's price could rise from here. Traders may explore going long the stock or buying call options...

Verastem (VSTM, $12.03) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Verastem (VSTM, $11.91) price moved above its 50-day Moving Average on March 21, 2024

Verastem (VSTM, $11.83) price moved above its 50-day Moving Average on March 20, 2024

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Watchers	23,008
52-Wk Low	$4.93
52-Wk High	$15.18

Volume	137,668.00
52-Wk High	$15.18
52-Wk Low	$4.93

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.99	--	--	N/A
Q1'24	-$1.03	-$1.26	-22.16%	MISSED
Q4'23	-$0.61	-$1.02	-66.82%	MISSED
Q3'23	-$0.84	-$0.75	11.02%	BEAT
Q2'23	-$1.04	-$1.37	-31.31%	MISSED

VSTM Verastem Inc

About

Feed

News

Sentiment

Earnings

Fundamentals